Neonatal Abstinence Syndrome (NAS)
The increasing use of opioid analgesics has also affected patterns of use by women of child bearing age and is associated with an increasing prevalence of newborns whole display symptoms of opioid withdrawal after delivery.
Neonatal abstinence syndrome (NAS) is a constellation of physiologic and neurobehavioral manifestations (drug withdrawal syndrome) exhibited by newborns who have been exposed in utero to prescription or illicit drugs capable of producing tolerance and physical dependence. NAS most commonly occurs in neonates with sufficient exposure to prescription opioids, buprenorphine or methadone in the context of medication-assisted therapy, or illicit opioids, including heroin. Typically manifesting in the first day or two of life, affected neonates may exhibit "hypertonia, autonomic instability, irritability, poor suckling reflex, impaired weight gain, and less commonly seizures. " 1 Although medically-appropriate opioid use in pregnancy is not uncommon, there has been a renewed focus on maternal opioid dependence, opioid exposure during pregnancy, and infants born with NAS.
NAS increased threefold from 2000 to 2009, and increased another 70% between 2009 and 2012; during the same time period maternal opioid use increased more than four-fold. 2, 3 Aggregate hospital charges for NAS increased from $732 million to $1.5 billion (P<0.001), with 81% attributed to state Medicaid programs in 2012.
In September 2013 the FDA instituted a black box warning for extended-release opiates, warning of "life-threatening neonatal opioid withdrawal syndrome" despite the fact that there is no evidence of infant death from this syndrome. In February 2015 the GAO released a report on prenatal drug use and newborn health and concluded that "federal efforts need better planning and coordination. " 4 More research has been done on NAS and two recent federally funded studies published in 2019 have identified factors that affect the risk for and severity of neonatal abstinence syndrome (NAS) and suggest that reducing expectant mothers' polysubstance use during buprenorphine treatment for opioid use disorder is an important goal for reducing NAS severity.
The first NIDA-sponsored study done at Vanderbilt University found higher rates of NAS among males than among females. A second study found that, among infants whose mothers were treated with buprenorphine while pregnant, NAS was more severe among those whose mothers used illicit drugs or misused prescription drugs.
In the second study, Dr. Lauren Jansson and colleagues from Johns Hopkins University recorded 41 mothers' buprenorphine doses and other substance use during pregnancy and assessed their newborns for NAS. Twenty-four of the infants developed NAS symptoms severe enough to require morphine for relief. The researchers' analysis linked maternal polysubstance use to greater infant NAS severity. Infants whose mothers used other substances besides buprenorphine while pregnant required almost 10 times more morphine for NAS than infants whose mothers took only buprenorphine. 5 Studies also link rates of NAS with social determinants. A NIDA-funded analysis of eight states showed a significant association between rates of neonatal abstinence syndrome (NAS) and poor economic conditions.
The study determined that areas with higher rates of long-term unemployment and a shortage of mental health professionals were likely to have proportionately more cases of NAS. The investigators point out that there is no clear consensus as to why the lack of economic opportunity contributes to the increased misuse of opioids in any given county, only that economic conditions might contribute to the high rates of NAS. 6 
